期刊文献+

烧伤病区抗菌药物使用9年的回顾性分析 被引量:3

Nine-year Use of Antibiotics in a Burn Unit: A Retrospective Analysis
下载PDF
导出
摘要 目的分析烧伤抗感染治疗用药的变化趋势,为促进合理使用抗菌药物、提高临床抗感染治疗水平积累经验并提供参考。方法采用平均100例患者每日使用约定剂量(DDDs/100例.d)作为抗菌药物使用量的观察指标,对烧伤病区1995-2003年抗菌药物使用的数据进行统计,并统计同期病原菌不同革兰染色类型所占比例,作为评价抗菌药物使用合理性的参照。结果9年来烧伤临床抗菌药物使用量无明显增加的趋势,2003年含酶抑制剂类药物取代氨基糖苷类药物成为使用量最大的抗菌药物;1995年后革兰阳性菌在病原菌中所占比例逐渐升高,2003年已超过革兰阴性菌。结论烧伤病区对抗菌药物的使用实行了有效的总量控制;今后应重点加大对革兰阳性菌感染治疗的力度。 OBJECTIVE TO analyze the use of antibiotic METHODS The data of consumption of different kinds of in the burn unit of our hospital from 1995 to 2003. antibiotics and total antibiotic consumption [-expressed as the number of defined daily doses (DDD) per 100 patients per day], as well as the proportion of Gram positive and Gram negative bacteria in isolated strains from burn patients was calculated in a nine-year period. RESULTS The total consumption of combination of antibiotic and β-lactamase inhibitor (compound drugs) was increased gradually and ranked first among all kinds of antibiotics, but there was no trend of increase observed in total amount of consumption of antibiotics. The proportion of Gram positive bacteria was increased markedly, exceeding that of the Gram negative ones in 2003. CONCLUSIONS The measures to control total amount of consumption of antibiotics and to promote judicious use of antibiotics may be beneficial in the prevention and treatment of infections in the burn unit. To pay more attention on the prevention and treatment of Gram positive infection should be emphasized to mitigate the tendency of increase in Gram positive bacteria infection.
出处 《中华医院感染学杂志》 CAS CSCD 北大核心 2006年第12期1403-1405,共3页 Chinese Journal of Nosocomiology
关键词 抗菌药物 烧伤 感染 每日约定剂量 Antibiotic Burns Infection Defined daily doses
  • 相关文献

参考文献8

二级参考文献31

  • 1王小万.药物经济学的基本理论与方法[J].国外医学(卫生经济分册),1994,11(4):159-160. 被引量:5
  • 2刘俊英,蔡景一,杨淑蓉,李忠芬,王新红.对临床使用抗生素的调查与分析[J].中华医院管理杂志,1994,10(1):31-33. 被引量:5
  • 3张荣富.外科抗生素预防中的微生物因素[J].国外医药:抗生素分册,1994,5:367-367.
  • 4..医院感染管理规范[S].中华人民共和国卫生部,2000,15-20..
  • 5[1]Akio K,Hisakazu Y,Ryoichi O,et al.Antibacterial activity of β-lactam antibiotics against extended-spectrum β-lactamase producing bacteria[J].Jpn J Antibiot,1999,52(9): 585-594.
  • 6[2]National Committee for Clinical Laboratory Standards.MIC testing supplement tables[S].M100-S13(M7).NCCLS,2003.
  • 7[3]Wang H,Dzink-Fox JL,Chen MJ,et al.Genetic characterization of highly fluoroquinolone-resistant clinical Escherichia coli strains from China: role of acrR mutations[J].Antimicrob Agents Chemother,2001,45(5): 1515-1521.
  • 8[4]Wang H,Kelkar S,Wu WY,et al.Clinical isolates of Enterobacteriaceae producing extended-spectrum beta-lactamases: prevalence of CTX-M-3 at a hospital in China[J].Antimicrob Agents Chemother,2003,47(2): 790-793.
  • 9[1]Jacoby GA,Mederiros AA. More extended-spectrum β-lactamases[J]. Antimicrob Agents Chemother,1991, 35(9):1697-1704.
  • 10[4]Sanders CC,Barry AL, Washington JA, et al. Detection of extended-spectrum β-lactamases-producing members of the family Enterobacteriaceae with the VITEK ESBLs test [J]. J Clin Microbiol, 1996,34(12): 2997-3001.

共引文献435

同被引文献35

引证文献3

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部